HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.1%

Neg 0% Neu 86.1% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.